Furmonertinib

Abbisko Cayman Limited has started a Phase II trial for ABSK043, an oral PD-L1 inhibitor combined with furmonertinib to treat advanced non-small cell lung cancer with EGFR mutations, aiming to boost anti-tumor efficacy. Investors should be cautious as drug success is uncertain.

98 patients with advanced EGFRm NSCLC received icotinib; 59.2% were female, median age 61 years. 82.7% had adenocarcinoma, 93.9% stage IV. 51% had EGFR Ex 19del, 49% EGFR L858R. 79.6% experienced disease progression, 61.2% died. ORR was 68%, DCR 93%, median PFS 10.7 months, median OS 29.9 months. 71.4% had baseline detectable EGFRm ctDNA, 45.9% became undetectable after treatment. No significant difference in ORR or DOR between baseline detectable and undetectable EGFRm ctDNA. Group B (clearance) had higher ORR than Group C (non-clearance). PFS and OS were better in Group A/B vs. Group C.